Mackenzie Financial
CBAY

Mackenzie Financial’s Cymabay Therapeutics CBAY Stock Holding History

Mackenzie Financial’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35,660
Closed -$417K – 1614
2023
Q2 		$417K Sell
35,660
-14,518
-29% -$135K ﹤0.01% 1074
2023
Q1 		$438K Buy
+50,178
New +$402K ﹤0.01% 1059
2020
Q4 		– Sell
-121,200
Closed -$877K – 1104
2020
Q3 		$877K Buy
+121,200
New +$648K ﹤0.01% 686

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Mackenzie Financial's CBAY Position: Q3 2023 in Review

Mackenzie Financial sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 35,660 shares — an estimated $417K sold.

Mackenzie Financial first reported a position in CBAY in Q3 2020 and held it in 3 quarters. The position peaked at $877K in Q3 2020. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

  • Mackenzie Financial reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Mackenzie Financial sold 35,660 Cymabay Therapeutics shares in Q3 2023, an estimated $417K.
  • Mackenzie Financial first reported a position in Cymabay Therapeutics in Q3 2020 and held it in 3 quarters.
  • Mackenzie Financial's Cymabay Therapeutics position peaked at $877K in Q3 2020.
  • 189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Mackenzie Financial's 13F filing for Q3 2023, filed 25 Oct 2023.